In our study, combined treatment increased HT-29 (KRAS WT CRC) and HCT-116 (KRAS MT CRC) cell accumulation at the sub-G1 and S phases of the cell cycle compared to the control (Figure 2A,B). The gene discussed is KRAS; the disease is colorectal carcinoma.